PDCD1 and neoplasm: Agents blocking programed cell death protein-1 (PD-1) and its ligand PD-ligand-1 (PD-L1) are other examples of immune checkpoint molecules shown to have anti-tumor activity in solid malignancies and appear to have an improved safety profile compared to anti-CTLA-4 (29, 30).